한국 소아 수모세포종의 다기관 치료 성적

Abstract

Purpose: Medulloblastoma is the most common primary malignant brain tumor of childhood. In spite of improved multimodality approach, 30∼40% of children with medulloblastoma still suffer from recurrence. Furthermore, many survivors have significant long-term sequelae. This study was undertaken to investigate the current status of childhood medulloblastoma in Korea. Methods: Questionnaires were sent to the member hospitals of the Korean Society of Pediatric Neuro-Oncology. One hundred and sixty seven cases from 20 university hospitals were collected and analyzed. Results: The median age at diagnosis was 6.9 years and the male to female ratio was 1.9：1. Patients in average risk group were 77 (46%) and those in high risk group were 90 (54%). In average risk group, 1 patient was treated with operation only, 4 were treated with operation and radiotherapy, 70 were treated with operation, radiotherapy and chemotherapy, 2 were treated with various treatments. In high risk group, 4 patients were treated with operation and radiotherapy, 9 were treated with operation and chemotherapy, 58 were treated with operation, radiotherapy and chemotherapy, 16 were treated with high dose chemotherapy and autologous stem cell rescue, and 3 were treated with various treatments. Median follow up was at 30.8 months, and 3 year EFS was 65% for all patients. The 3 year EFS were 78% for patients in average risk group and 54% for patients in high risk group. Conclusion: Diverse treatment protocols have been applied for childhood medulloblastoma in Korea. This study inspired the necessity of nation-wide protocols and prospective multicenter studies for medulloblastoma in Korea.